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VULGARIS WHILE USING DIFFERENT
THERAPIES
Abstract. The paper presents a dynamics of phagocytocis indices in
patients with acne vulgaris while using different therapies. It has
been established that the use of comprehensive treatment with
administration of a probiotic "Lacium" and an immunocorrective
drug "Licopid" for patients with moderate and severe acne vulgaris
combined with intestinal dysbiosis and lower activity of blood
phagocytes, contributes to normalization of blood indices, charac-
terizing the initial and final stages of phagocytic process.
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Introduction
Optimizing the treatment of acne vulgaris is the
important task of modern dermatology. Acne vul-
garis is one of the most common skin diseases
among youth and young working age [3, 11, 12].
Chronic Acne vulgaris, the development of a rash on
exposed skin areas (face, shoulders, upper trunk),
frequent formation of persistent skin scarring (post-
acne) is the cause of psycho-emotional disorders in
patients and deterioration in quality of their life [1, 13,
14].
In recent years, Acne vulgaris is characterized by
more severe clinical course with frequent prolonged
relapses, torpid to the means of standard therapy,
justifying the relevance of scientific research to de-
termine the pathogenic factors and optimize their
treatment [2, 7, 15].
 It has been established that the pathogenesis
Acne vulgaris is complex and multifactorial, der-
matitis occurs in individuals against the backdrop of
genetic predisposition with disorders of the en-
docrine regulation of systemic immunity, metabolic
disorders, the presence of chronic foci of infection,
etc. [1-3, 6]. Previous studies in patients with Acne
vulgaris discovered changes of phagocytosis and
disturbances in  intestinal ecosystems that are
dependent on the severity of clinical manifestations
of dermatosis their probable changes were found in
patients with moderate and severe acne [4, 5, 11],
which proves the feasibility of differentiated admi-
nistration of probiotics and immunocorrective drugs in
comprehensive therapy for Acne vulgaris.
Objectives
To identify and analyze the dynamics of pha-
gocytosis indices in patients with acne vulgaris under
different treatments - standard and integrated with
the use of probiotics and immunocorrective drugs.
Materials and methods
67 patients with acne vulgaris, including 29 male
patients and 38  women aged from 18 to 29 years
old were involved in the study The criteria for inc-
lusion into the study were the following: clinical
manifestations of moderate and severe acne; pa-
tient's age - 18 years or more; absence of chronic
physical illnesses or their exacerbation at the time of
the examination. According to clinical criteria of acne
vulgaris [3], the majority (49 - 73,1%) of the patients
were diagnosed with moderate acne, while 17
(25,4%) of them had severe form of acne with der-
matosis duration from 1,5 to 12 years. The control
group included 35 healthy individuals (donors) of the
same age.
In order to assess the state of phagocytosis in
patients with acne vulgaris, we determined phagocytic
activity (PA) and phagocytic index (PI) of poly-
morphonuclear leukocytes, nitro blue tetrazolium
recovery test (NBT test spontaneous) and NBT-test
pyrogenal stimulated by known methods [10]. Sta-
tistical analysis of the results of research was carried
out by the methods of statistical analysis [8] using
software (Excel, Statistica 6.0), the difference of
averages was considered probable at p<0,05.
Results and discussion
By determininng the phagocytosis  indices in 67
patients with moderate and severe acne vulgaris at
the beginning of the treatment, we revealed a sig-
nificant reduction in PI (10,5%, p=0,008) compared
with those in control group in patients with acne
5,11±0,113, in patients of control group - 5,71±0,220),
which reflects the initial stages of phagocytic pro-
cess, and we olso noticed a drop of  spontaneous
NBT-test (by 43,15%, p<0,001; in patients with acne
- 11,2±0,654, and in the control group - 19,7±0,775),
which is characteristic for  the final stages of the
phagocytic process. However, the majority (61 -
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91,1%) of examined patients had manifestations of
associated intestinal dysbiosis of the I-IV degrees.
In the process of treatment, patients with acne
were divided into 3 groups randomly, comparable in
age, sex and distribution of patients according the
severity of dermatosis: the patient of the first group
(22 persons) received basic acne treatment [9], pa-
tients of group II (22 people) were additionally admi-
nistered a probiotic "Lacium", patients of group III
(23 people) were administered a probiotic "Lacium"
along with basic therapy(1 sachet twice a day 30
minutes before meals, for 14 days) and immu-
nocorrective drug "Licopid" (1 mg sublingually 30
minutes before meals for 10 days), which has sti-
mulating effect on cellular immunity in general and
phagocytic activity of phagocytic cells in particular.
The dynamics of phagocytosis indices in  patients
with acne vulgaris due to using different therapies is
presented in the table.
The results of the studies in patients with acne
Òable
Evolution of phagocytosis indices in patients with acne vulgaris after different therapies
(M±m)
Patients with acne vulgaris (n=67) Indices, measurement 
units 1st group  
(n1=22) 
2nd group 
(n2=22) 
3rd  group 
 (n3=23) 
Control 
group 
(n=35) 
Before 
treatment 
68,4±0,988 69,1±1,01 
p1-2=0,623 
67,3±0,835* 
p1-3=0,40; 
 p2-3=0,177 
Phagocytic 
activity, % 
After 
treatment 
66,7±0,973
* 
 
68,9±0,939 
p1-2=0,111 
73,9±1,43 
p1-3<0,001; p2-
3=0,006 
Ð (before/after treatment) Ð=0,227 Ð=0,885 Ð<0,001 
70,6± 
1,17 
 
Before 
treatment 
5,10±0,158 5,24±0,235 
p1-2=0,624 
4,98±0,189* 
p1-3=0,629;  
p2-3=0,394 
Phagocytic index 
After 
treatment 
5,02±0,135
* 
 
5,96±0,331 
p1-2=0,012 
6,17±0,255 
p1-3<0,001; 
 p2-3=0,618 
Ð (before/after treatment) Ð=0,702 Ð=0,083 Ð<0,001 
5,71± 
0,220 
 
Before 
treatment 
11,5±1,29**
* 
11,5±1,23**
* 
p1-2=1,0 
10,6±0,870*** 
p1-3=0,566;  
p2-3=0,552 
Spontaneous 
NBT-test 
After 
treatment 
9,11±0,323
*** 
 
10,6±0,524
*** 
p1-2=0,020 
13,3±1,06*** 
p1-3<0,001; 
 p2-3=0,028 
Ð (before/after treatment) Ð=0,079 Ð=0,505 Ð=0,056 
19,7± 
0,775 
 
Before 
treatment 
30,6±0,398 29,3±0,931  
p1-2=0,206 
28,0±0,664 
p1-3=0,002;  
p2-3=0,262 
Stimulated NBT 
test 
After 
treatment 
29,9±0,589 
 
31,3±0,512 
p1-2=0,08 
31,6±0,846 
p1-3=0,107;  
p2-3=0,762 
Ð (before/after treatment) Ð=0,330 Ð=0,067 Ð=0,002 
29,5± 
1,08 
 
Notes: 1. * – The degree of probability of the indices deference relative to control group of patients: 
            * – ð<0,05; ** – p<0,01; *** – p<0,001. 
2. p1-2, p1-3, p2-4 – probability of the indices deference in patients of different groups. 
3. Ð – probability of the indices deference in the groups of patients before and after the treatment. 
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vulgaris in the first camparison group, where a stan-
dard therapy was used, showed a tendency to dec-
reasing of  PA and PI, whereupon they became sig-
nificantly less relative to the same indices of the
people of control group (5,5% p=0,023 and 12,1%,
p=0,024 respectively).
Patients with acne vulgaris from the second com-
parative group, who received probiotic "Lacium"
along with the basic therapy, at the end of treatment
tended to increase PI with the significant difference
between the same index in the first comparative
group (an increase by 18,7%; p=0,012) without sig-
nificant alteration of other studied parameters of pha-
gocytosis.
However, patients with acne vulgaris in the core
group who received combined therapy with the inc-
lusion of probiotic "Lacium" and immunotropic drug
"Licopid" had a probable increase in both PI and PA
regarding their initial level (23,9% and 9,8 %, p<0,001
respectively), and the values of these parameters at
the end of treatment in patients from the first com-
parative group (22,9% and 10,8%, p<0,001 res-
pectively), as well as PA relative to values of PA in
patients from the second comparative group (by
7,3%, p=0,006).
 Patients of the core group, at the end of treat-
ment, also had significant increase of stimulated NBT
test (by 12,9%, p=0,002), and tended to increase
spontaneous NBT test of with its probable difference
having the same value as in the the 1st  and 2nd
comparative groups ( by 45,9%, p<0,001 and 25,5%,
p=0,028 respectively), but preserving significant
difference with the same rate in the control group (a
decrease by 32,5%, p<0,001).
The obtained better results on the evolution of the
phagocytosis indices in patients of the main group
compared to those from the comparative groups
could be related both to direct stimulating effect of
immunotropic drug on phagocytic blood cells, and
due to a decrease of microbial intestinal load on them
as a result of normalizing probiotic action on con-
comitant dysbiotic disturbances of the large intestine
in these patients.
Thus, an analysis of the results of different treat-
ments of patients with moderate and severe acne
vulgaris (basic, basic with probiotics) indicates that
the administration of probiotic "Lacium" and imuno-
corrective drug "Licopid" against the background of
basic therapy makes a normalizing effect on the lea-
ding phagocytosis rates of patients with acne, and
enhances their phagocytic activity both during cap-
ture and formation of bactericidal activity and in the
final stages of phagocytosis, justifying the feasibility
of a combined use of probiotics and immunotropic
drugs in combined treatment of the patients with
moderate and severe acne vulgaris.
Conclusion
Using combined therapy with the inclusion of
imunomotropic drug "Licopid" and a probiotic
"Lacium" for  patients with moderate and severe
acne vulgaris with concomitant intestinal dysbiosis
and lowering of phagocytic blood cells activity leads
to normalization or tendency to normalization of pha-
gocytosis indices, justifying the feasibility of using
these drugs  in the combined treatment of these pa-
tients.
Prospects for further research
In the future we are going to determine and ana-
lyse the dynamics of other homeostasis indices in a
combined treatment of patients, having moderate and
severe acne vulgaris, by using immunotropic  and
probiotic drugs.
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